Who can use Xiidra(Lifitegrast)?

Xiidra (lifitegrast ophthalmic solution 5%) is indicated for treating signs and symptoms of dry eye disease (DED).

Who can use Xiidra(Lifitegrast)?

Xiidra, a lymphocyte function-associated antigen-1 (LFA-1) antagonist, is FDA-approved for the management of both clinical signs and subjective symptoms of dry eye disease (DED). It acts by inhibiting LFA-1 binding to intercellular adhesion molecule-1 (ICAM-1), thereby disrupting T-cell-mediated inflammation implicated in DED pathogenesis. The indication is supported by four pivotal 12-week, randomized, vehicle-controlled trials involving 1,181 patients, demonstrating efficacy in reducing corneal staining (a sign) and improving patient-reported eye dryness (a symptom). The therapy is intended for topical ophthalmic use twice daily, with no restrictions regarding DED severity subtypes (e.g., aqueous-deficient or evaporative). Safety and efficacy in pediatric patients under 17 years remain unestablished.